about
Guidance for the management of venous thrombosis in unusual sitesAntithrombotic treatment of splanchnic vein thrombosis: results of an international registry.Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.Bleeding complications during anticoagulant treatment in patients with cancer.Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registrySafety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registryTrousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux.Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useCancer in males and risk of venous thromboembolism.Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery.Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism.Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry.Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs.Direct Oral Anticoagulants and Women.Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses.Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients' preference.Small clots with large impact.Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.Fibrinolysis for patients with intermediate-risk pulmonary embolism.Predictors of deep venous thrombosis in patients admitted to rehabilitation clinics after major orthopaedic surgery.Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients.Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients.The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease.Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol.Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis.What have we learned from real-world NOAC studies in venous thromboembolism treatment?Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
P50
Q28078201-8A5673DB-CD35-4196-B9EE-EF1685C6FC25Q33412386-B09A9580-AECE-4924-813D-BA727CB93263Q33414430-A361722B-5A0B-4D81-95EA-6401BBFC76B8Q33415521-1D1297A8-AD64-4CD5-9E8D-C5AC6C273C8BQ34019616-B7B0B622-35CB-4C4B-B2AD-09384289D4C1Q34554492-C6581463-13E8-4B9D-B293-1564E4664EF4Q35154171-B7111E3B-F740-458C-B52C-F58B9344727AQ35239819-04D7BA6B-FABB-42B4-8791-5D049CE4D7C8Q35373738-DF005265-2B51-413C-880C-3DE2823CF1F1Q36468119-26301966-6D13-4FA6-9434-AA0DD187D1A7Q36800361-09C22040-C574-4DDC-A599-EF97F545DAA2Q37740301-2B418B4D-7B92-4CB8-B493-7A7987B2682AQ38006688-266F969A-2195-44E6-B482-71BB17B39D78Q38378114-C077BF6E-CB7E-4231-AB31-B9649BF997EEQ38441382-7C9678C9-005F-44AC-993D-DE60EA06E7EDQ38458642-C03BC030-ADE6-4AE5-9807-20FE394AD333Q38712843-28053B00-ED99-492E-8641-39476B7C021BQ38792641-E5524673-7CA8-4D3B-9B91-304D813FF433Q38955911-DB2FD614-767E-419C-A12A-D4E72B75752FQ38972829-94D029AB-5762-456E-B189-3DA77B2692E5Q39188663-B0638196-A15A-4050-9B9E-20CD5BC5B214Q40036641-BA34882B-6ABF-48C4-80A0-5F1E17516A4CQ40286342-C6B09F10-311F-409C-950A-12F61897B4F8Q40706195-66B414B4-BE10-4167-9584-9F5194D818A8Q41373585-A7256B24-CDCC-4601-A649-639BCFC972C1Q41464475-1EBD75D6-6048-4B5C-95CB-3E45455CED70Q41501792-906F3112-88A4-4193-AF07-8E49E7716B28Q45144900-58B828B7-C9C1-4A82-B0EC-ED211EB57759Q45416948-E6239BD9-5CAE-47A6-AB59-DC083450782BQ45727029-6A2AD636-D20C-4B60-BF2E-FFAB330EA096Q45841050-5091311B-C74E-4DCB-9C04-3A21F6F7B790Q45874939-723EB5AF-691A-4DFD-9FF8-B9D4F45D3462Q45903972-4497B1E9-7F07-4D1A-ADF4-0AC85DABEF7AQ46315041-65E33F18-1464-4954-A0A7-AA11D0AD0535Q47202261-5D930584-E7E3-40D9-A8C3-898B37250429Q48033772-CB81F87A-2097-4D97-AA32-803E86A4A05EQ48163723-96D6D1F5-2BCB-4BB7-B7AC-7440FB04D57CQ49989182-D3BDABA1-198B-493B-BEF1-1302F73D9066Q50174443-B750EE7D-817C-40B5-BA2B-917A7E24B93AQ50174505-AF55DF0B-B95C-43F1-AF28-A783ED0FF40E
P50
name
Jan Beyer-Westendorf
@ast
Jan Beyer-Westendorf
@en
Jan Beyer-Westendorf
@es
Jan Beyer-Westendorf
@nl
type
label
Jan Beyer-Westendorf
@ast
Jan Beyer-Westendorf
@en
Jan Beyer-Westendorf
@es
Jan Beyer-Westendorf
@nl
prefLabel
Jan Beyer-Westendorf
@ast
Jan Beyer-Westendorf
@en
Jan Beyer-Westendorf
@es
Jan Beyer-Westendorf
@nl